Toll-like receptor 4 signal transduction inhibitor, M62812, suppresses endothelial cell and leukocyte activation and prevents lethal septic shock in mice

European Journal of Pharmacology

Volumn 569, Issue 3, 2007, Pages 237-243

  Nakamura, Masaki ^a   Shimizu, Yusuke ^a   Sato, Yasuko ^a   Miyazaki, Yutaka ^a   Satoh, Tsutomu ^a   Mizuno, Masashi ^a   Kato, Yutaka ^a   Hosaka, Yoshitaka ^a   Furusako, Shoji ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Lipopolysaccharide; Sepsis; Toll like receptor 4

Indexed keywords

3 AMINO 6 (2 AMINOPHENOXY) 1,2 BENZISOTHIAZOLE DIHYDROCHLORIDE; CELL ADHESION MOLECULE; CYTOKINE; ENDOTOXIN; GALACTOSAMINE; LIPOPOLYSACCHARIDE; M 62812; PROCOAGULANT; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR 4 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CECUM; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; LETHALITY; LEUKOCYTE ACTIVATION; LIGATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNCTURE; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTOXINS; HUMANS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; THIAZOLES; TOLL-LIKE RECEPTOR 4; UMBILICAL VEINS; UP-REGULATION;

EID: 34547582255     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.013     Document Type: Article

References (28)

1. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev., Immunol. 4 (2004) 499-511
2. Allary J., and Annane D. Glucocorticoids and sepsis. Minerva Anestesiol. 71 (2005) 759-768
3. Alves-Filho J.C., de Freitas A., Russo M., and Cunha F.Q. Toll-like receptor 4 signaling leads to neutrophil migration impairment in polymicrobial sepsis. Crit. Care Med. 34 (2006) 461-470
4. Andonegui G., Bonder C.S., Green F., Mullaly S.C., Zbytnuik L., Raharjo E., and Kubes P. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J. Clin. Invest. 111 (2003) 1011-1020
5. Annane D., Bellissant E., and Cavaillon J.M. Septic shock. Lancet 365 (2005) 63-78
6. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., Fisher Jr. C.J., and Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001) 699-709
7. Buras J.A., Holzmann B., and Sitkovsky M. Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4 (2005) 854-865
8. Creasey A.A., Chang A.C., Feigen L., Wun T.C., Taylor Jr. F.B., and Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91 (1993) 2850-2860
9. Dackiw A.P., McGilvray I.D., Woodside M., Nathens A.B., Marshall J.C., and Rotstein O.D. Prevention of endotoxin-induced mortality by antitissue factor immunization. Arch. Surg. 131 (1996) 1273-1278
10. Galanos C., Freudenberg M.A., and Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 5939-5943
11. Guha M., and Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 13 (2001) 85-94
12. Hawkins L.D., Ishizaka S.T., McGuinness P., Zhang H., Gavin W., DeCosta B., Meng Z., Yang H., Mullarkey M., Young D.W., Yang H., Rossignol D.P., Nault A., Rose J., Przetak M., Chow J.C., and Gusovsky F. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J. Pharmacol. Exp. Ther. 300 (2002) 655-661
13. Ii M., Matsunaga N., Hazeki K., Nakamura K., Takashima K., Seya T., Hazeki O., Kitazaki T., and Iizawa Y. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69 (2006) 1288-1295
14. Ishii H., and Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappaB/Rel. Toxicol. Appl. Pharmacol. 184 (2002) 88-97
15. Liokins M.S., and Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet 362 (2003) 1828-1838
16. Lolis E., and Bucala R. Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat. Rev. Drug Discov. 2 (2003) 635-645
17. Matsukawa A., Lukacs N.W., Hogaboam C.M., Knibbs R.N., Bullard D.C., Kunkel S.L., and Stoolman L.M. Mice genetically lacking endothelial selectins are resistant to the lethality in septic peritonitis. Exp. Mol. Pathol. 72 (2002) 68-76
18. Mullarkey M., Rose J.R., Bristol J., Kawata T., Kimura A., Kobayashi S., Przetak M., Chow J., Gusovsky F., Christ W.J., and Rossignol D.P. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304 (2003) 1093-1102
19. Opal S.M., and Gluck T. Endotoxin as a drug target. Crit. Care Med. 31 (2003) S57-S64 (Suppl.)
20. Riedemann N.C., Guo R.F., and Ward P.A. Novel strategies for the treatment of sepsis. Nat. Med. 9 (2003) 517-524
21. Rossignol D.P., and Lynn M. TLR4 antagonists for endotoxemia and beyond. Curr. Opin. Investig. Drugs 6 (2005) 496-502
22. Russell J.A. Management of sepsis. N. Engl. J. Med. 355 (2006) 1699-1713 2006
23. Villa P., Sartor G., Angelini M., Sironi M., Conni M., Gnocchi P., Isetta A.M., Grau G., Buurman W., van Tits L.J., and Ghezzi P. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin. Diagn. Lab. Immunol. 2 (1995) 549-553
24. Wichterman K.A., Baue A.E., and Chaudry I.H. Sepsis and septic shock-a review of laboratory models and a proposal. Surg. Res. 29 (1980) 189-201
25. Wiedermann C.J., Hoffmann J.N., Juers M., Ostermann H., Kienast J., Briegel J., Strauss R., Keinecke H.O., Warren B.L., Opal S.M., and KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit. Care Med. 34 (2006) 285-292
26. Williams D.L., Ha T., Li C., Kalbfleisch J.H., Schweitzer J., Vogt W., and Browder I.W. Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit. Care Med. 31 (2003) 1808-1818
27. Xu H., Gonzalo J.A., St. Pierre Y., Williams I.R., Kupper T.S., Cotran R.S., Springer T.A., and Gutierrez-Ramos J.C. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J. Exp. Med. 180 (1994) 95-109
28. Yamada M., Ichikawa T., Ii M., Sunamoto M., Itoh K., Tamura N., and Kitazaki T. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl) cyclohex-1-1ene-1-carboxylate. J. Med. Chem. 48 (2005) 7457-7467